This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Dermatologic Disorders  • Rheumatology  • Statistics and Research Methods  • Rheumatoid Arthritis  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Research Advances in Rheumatoid Arthritis

William J. Koopman, MD

JAMA. 2001;285:648-650.

Rheumatoid arthritis (RA) is a common chronic inflammatory disease associated with progressive destruction of diarthrodial joints, substantial morbidity and economic burden, and a shortened lifespan. Significant progress has been made in understanding the pathogenesis of RA, and increasingly effective therapies have been introduced, including anti–tumor necrosis factor agents. Advances made in the past quarter century will pale in comparison to those anticipated for the next 25 years, including delineation of the genetic basis of disease susceptibility and severity, genetic definition of disease subtypes that differ in severity and response to therapy, and prompt initiation of effective individualized treatment based on genetic and environmental assessment. Reconstructive surgery will become increasingly unnecessary and the morbidity, economic burden, and mortality due to RA will be reduced substantially.

Author Affiliation: Department of Medicine, University of Alabama at Birmingham.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Vaccination without Autoantigen Protects against Collagen II-Induced Arthritis via Immune Deviation and Regulatory T Cells
Kochetkova et al.
J. Immunol. 2008;181:2741-2752.
ABSTRACT | FULL TEXT  

Efficacy and safety of the fully human anti-tumour necrosis factor {alpha} monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
van de Putte et al.
Ann Rheum Dis 2003;62:1168-1177.
ABSTRACT | FULL TEXT  

Depletion of Collagen II-Reactive T Cells and Blocking of B Cell Activation Prevents Collagen II-Induced Arthritis in DBA/1j Mice
Zhang et al.
J. Immunol. 2002;168:4164-4172.
ABSTRACT | FULL TEXT